Lanvis (Tioguanine)

Tioguanine is converted inside cells to thioguanine nucleotides, which are falsely incorporated into DNA and RNA. This incorporation disrupts normal nucleic acid synthesis, leading to faulty replication and triggering programmed cell death, especially in fast‑growing lymphoid and myeloid cells that drive the targeted diseases.

The dose of Lanvis is individualized. The prescribing clinician determines the appropriate amount based on the specific indication, patient weight, renal and hepatic function, and ongoing laboratory monitoring. No standard dose can be provided without a qualified medical assessment.

Safety data for tioguanine during pregnancy and lactation are limited. Because the drug can affect rapidly dividing cells, it may pose risks to the fetus or nursing infant. Use is only recommended when the potential therapeutic benefit outweighs the uncertain risks, and it should be decided by a qualified healthcare professional.

To request Lanvis, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Lanvis (tioguanine) belongs to the purine analog class, similar to mercaptopurine. Both drugs interfere with nucleic acid synthesis, but tioguanine often has a longer intracellular half‑life, which can allow less frequent dosing in some protocols. Choice between them depends on disease specifics, patient tolerance, and physician experience.

Lanvis should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product in a dry area and avoid exposure to high humidity. No refrigeration is required for this oral formulation.

Lanvis is taken orally, usually with a glass of water. It may be taken with or without food, but consistency with meals can help reduce gastrointestinal discomfort. The exact schedule—once daily or divided doses—depends on the prescribing clinician’s instructions.

The most serious adverse risks include severe bone‑marrow suppression leading to infections, anemia or bleeding; hepatic toxicity that can progress to liver failure; and the rare possibility of secondary malignancies. Patients should be monitored regularly for blood counts and liver function to detect these complications early.

Lanvis is contraindicated in patients with known hypersensitivity to tioguanine or any excipients, in those with severe hepatic impairment, and in individuals where the risk of immunosuppression outweighs benefit, such as untreated active infections. Pregnant women should only use it when clearly indicated by a physician.